Onesource Specialty Pharma Limited — Q3 FY26 earnings call

Call held 24 Jan 2026

Management summary

OneSource Specialty Pharma Limited reported a challenging Q3 FY26 with a 26% YoY revenue decline to INR 2,903 million and an adjusted PAT loss of INR 472 million, primarily due to deferred semaglutide approvals in Canada. Despite near-term softness expected, the company reiterated its FY28 guidance of $400 million revenue and $160 million EBITDA, driven by expanding order books, new customer wins in biologics, and strategic capacity expansions. The company also achieved credit rating upgrades, reducing its cost of debt.

Highlights

  • Reiterated FY28 guidance of $400 million revenue and $160 million EBITDA, excluding inorganic accretions.

  • Order books continue to expand, and customer forecasts are being revised upwards.

  • Onboarded a new US-based biosimilar major customer.

  • Secured approval for the first oncology asset and partnered with a top 10 US generic company.

  • Received two credit rating upgrades, resulting in a 200 bps reduction in the cost of debt to less than 9% effective interest rate.

  • Aggressive capex of over INR 700 crores to increase capacities is progressing well, with $75 million committed for flagship DDC site expansion.

Concerns

  • Q3 FY26 revenue declined 26% YoY to INR 2,903 million due to deferred semaglutide approvals in Canada.

  • EBITDA was INR 173 million, and Adjusted PAT was a loss of INR 472 million, with Adjusted EPS at negative 4.1 per share.

  • Anticipate the next two quarters (H2 FY26 and H1 FY27) to remain relatively soft due to approval delays and negative operating leverage.

  • Inventory build-up for semaglutide launches, though customer-backed, impacts working capital.

Key financials

  1. Revenue 2,903 Mn -26%YoY
  2. EBITDA 173 Mn
  3. Adjusted PAT -472 Mn
  4. Adjusted EPS ₹-4.1

What they filed

Q1 FY27: revenue up 37.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue334 393 426 327 376 +13%290 −26%428 +0%449 +37%
EBITDA77 142 183 88 106 +38%17 −88%92 −50%123 +40%
Net profit-42 -69 98 0 10 +124%-89 −29%5 −95%25
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Capex $100 Mn
    • Increase capacities (overall) ₹700 Cr
    • Flagship DDC site expansion $75 Mn
    • Sterile facility upgrades (lyophilization, pre-filled syringes)
    Having said that, our aggressive capex of over INR700 crores to increase capacities are progressing very well, and we believe that by H2 FY '27, we will have significant additional capacities that will come up for increased demand as we see. (Arun Kumar, page 5) And as of last month, we have already committed almost three quarters of our total planned 100 million capex investment spend which we have set for our flagship site. (Neeraj Sharma, page 7) Our flagship site, obviously, there is absolutely no shutdown there in the flagship DDC site. The expansion which I mentioned, we continue to in fact, we already committed almost $75 million in that expansion. (Neeraj Sharma, page 9)
  • Debt 1.5× EBITDA Cost 9%
    • Rate reset Cost of debt 200 bps lower versus last year, less than 9% effective interest rate.
    However, we are very confident of the near-term guidance of less than 1.5x of EBITDA as our net borrowing. (Anurag Bhagania, page 9)
  • M&A Two injectable facilities Acquisition · Pending regulatory
    Okay. Okay. And a final one from my end. So, we had previously, announced the acquisition of the two injectable facilities. So, where are we in the transaction right now? Yes. Hi. This is Anurag. The process is working very well. It has moved forward. When we, spoke last, it was an application submitted to the Stock Exchange. There is a discussion between the Stock Exchange and SEBI. You know, process is working very well. We anticipate, us to be able to get the final all regulatory approvals in place by third quarter of FY27. (Anurag Bhagania, page 17)

Guidance & targets

Revenue

  • FY28 Revenue (organic) Revenue · FY28 · High confidence $400 million
    At the time of our listing in January 2025, the singular guidance that we have provided to investors is a number of $400 million, with an EBITDA of $160 million for FY '28. (Arun Kumar, page 4)

    — Arun Kumar

  • CSA Revenues Revenue · FY27 · High confidence material
    FY '27 will mark the beginning of material CSA revenues with H2 significantly stronger than H1. (Arun Kumar, page 5)

    — Arun Kumar

  • Q4 FY27 Exit Run Rate Revenue · Q4 FY27 · High confidence good reflection of near-close FY '28 guidance numbers
    I expect a Q4 FY '27-analyzed exit run rate for both revenues and EBITDA to be a good reflection of near-close FY '28 guidance numbers. (Arun Kumar, page 5)

    — Arun Kumar

EBITDA

  • FY28 EBITDA EBITDA · FY28 · High confidence $160 million
    At the time of our listing in January 2025, the singular guidance that we have provided to investors is a number of $400 million, with an EBITDA of $160 million for FY '28. (Arun Kumar, page 4)

    — Arun Kumar

Debt

  • Net Debt to EBITDA (near-term) Debt · Near-term · High confidence less than 1.5x
    However, we are very confident of the near-term guidance of less than 1.5x of EBITDA as our net borrowing. (Anurag Bhagania, page 9)

    — Anurag Bhagania

  • Net Debt to EBITDA (peak FY28) Debt · FY28 · High confidence less than 1.5x
    And secondly, just the last one on this, on the guidance that you put out you've talked about a debt to EBITDA peak guidance of less than one and a half times for FY28. (Nitin Agarwal, page 12)

    — Nitin Agarwal

  • Debt Status Debt · by 2028 · High confidence debt free
    So while on the base business, on a steady state, we expect to be debt free by 28. (Arun Kumar, page 12)

    — Arun Kumar

Capacity

  • Installed Capacity Capacity · end of FY27 · Medium confidence ~200 million
    They are as we have said we are in by end of the financial year FY27, we would be having, almost, let's say, installed almost 200 odd million. (Neeraj Sharma, page 12)

    — Neeraj Sharma

M&A

  • Injectable Facilities Acquisition Approvals M&A · Q3 FY27 · High confidence final all regulatory approvals in place
    We anticipate, us to be able to get the final all regulatory approvals in place by third quarter of FY27. (Anurag Bhagania, page 17)

    — Anurag Bhagania

What to watch in Q4 FY26

Canadian Semaglutide Approvals

Next quarter (Q4 FY26)
Current Delayed, estimated anytime between now and May 2026
Target Specific approval announcements

Why it matters

Key driver for revenue ramp-up and achieving FY28 guidance.

We believe, and based on their guidance, that their approvals are estimated anytime between now and May, and we also believe that other filers from our facility for the Canadian market will be in that range a little later. (Arun Kumar, page 4)

Risks & concerns

  • Canadian Semaglutide Approval Delays

    high

    Deferred revenues due to delays in Canadian regulatory approval for semaglutide, impacting Q3 results and expected to cause near-term softness.

    Management acknowledged

  • Softness in H2 FY26 and H1 FY27

    high

    The next two quarters are expected to remain soft due to deferred revenues and negative operating leverage from approval delays and absence of new MSAs.

    Management acknowledged

  • Suboptimal Batch Sizes

    medium

    Current batch sizes are suboptimal and not commercially viable for large production runs, requiring regulatory approvals for scale-up.

    Management working on it

  • Competitive Indian Market

    medium

    The Indian market has severe competitive intensity, though it is not a primary focus for the company.

    Management acknowledged

  • Inventory Build-up

    medium

    Inventory build-up for semaglutide launches, but it is customer-backed with advances or firm purchase orders and expected to normalize.

    Management downplayed

Q&A highlights

8 direct
Plant shutdown impact and DDC plant expansion Direct
This is not the flagship DDC site. The expansion plan there goes absolutely on track. The plant Arun was referring to was the general injectable site, which is in Bangalore. And that's a site which is one of the oldest sites in the group where we supply general injectables. And that's the site where we are adding capacities in lyophilization. We are adding some new capabilities.

Clarified that the shutdown was for a different facility and for capacity upgrades, not impacting the flagship DDC site's expansion.

Asked by Abdulkader Puranwala

Working capital, inventory pileup, and launch delays Direct
Abdul, as we are a CDMO, as you imagine, whatever inventory comes to us from our customers, it belongs to the customers. Obviously, we have all the procurement has been done in conjunction, in agreement with the customers, and the delays are actually on their side. As a CDMO, all inventory risk, if that's your question, actually belongs to the customers.

Addressed concerns about working capital and inventory risk, clarifying that the risk lies with customers as per CDMO model.

Asked by Abdulkader Puranwala

Peak capacity utilization and batch size increase Direct
When we run commercial campaigns, we can do, for example, as many as six batches in 7 days. However, when we end up doing MSAs, we end up doing only two batches in seven days. So purely from number of cartridges, it would be you can imagine less than a third of the commercial. So we don't always look at the number of cartridges coming out while it is in the MSA phase... if we make a batch of, let's say, 200 liter and a certain quantity comes out per day, in the same day if we are able to increase the batch size to 500 liter, the output becomes two and a half times that within the same time taken.

Explained the difference in output between MSA and commercial phases and how batch size increases, requiring regulatory approval, significantly boost capacity.

Asked by Rupesh Tatiya

Renegotiating take-or-pay agreements Direct
What we gain from being acting like partners and not like mercenary CDMOs is to really gain a long term partnership with the customers to ensure because we know that the changes which are there are not because of any inherent gap either in their demand forecast or in their willingness to buy. It is purely based on regulatory delays. And that's the reason we are being flexible with some of our key customers, gain their trust, gain their long term relationship.

Provided strategic rationale for renegotiating contracts, emphasizing long-term partnership and trust over short-term enforcement.

Asked by Nitin Agarwal

Biologics CDMO business trajectory Direct
What it really does is to actually accelerate the entire diversification, the geographical diversification plan for companies. And that is resulting in a lot of bio-techs, big pharma American, Japanese, European looking at India, especially OneSource as a positive as a probable site for drug substance... And something which is more immediate and near-term has been the change in the FDA guidelines on the biosimilar approval timelines which is -- what has happened there is that there's a -- thanks to the change in the guidelines, most biosimilars do not require now or will not require a clinical trial of Phase III.

Highlighted macro tailwinds (Biosecure Act, FDA guideline changes) that are accelerating the biologics CDMO business by reducing development costs and timelines.

Asked by Nitin Agarwal

Pricing divergence across countries due to regulatory barriers Direct
So Madhav as I said thank you for your question. But as I said earlier for us the market is completely immaterial. Our pricing with our customers is fixed. And it is based upon volumes and not volume tiers and not on end market. So whether they sell it in Canada or they sell it in India, or in Brazil or in Saudi Arabia, our pricing to our customers is the same.

Clarified that the company's pricing model is fixed with customers, volume-based, and not influenced by the end market or regulatory barriers.

Asked by Rupesh Tatiya

Oral GLP-1 adoption vs injectable capacity Direct
Oral will definitely have a place in the entire anti-obesity and diabetes regime... But having said that thanks to the difference in the efficacy levels. And because of the frequency of dosing, daily tablet versus a weekly injection. It is widely expected both by all major analysts as well as in fact the companies themselves, Lilly and Novo, have been very clear in saying that Oral will get a share but no more than a quarter to max a third of the total anti-obesity market.

Provided a nuanced view on the competitive landscape, indicating Oral GLP-1 will take a limited share of the anti-obesity market, thus not significantly impacting injectable capacity demand.

Asked by Abhishek Kumar Jain

Injectable facilities acquisition status Direct
Yes. Hi. This is Anurag. The process is working very well. It has moved forward. When we, spoke last, it was an application submitted to the Stock Exchange. There is a discussion between the Stock Exchange and SEBI. You know, process is working very well. We anticipate, us to be able to get the final all regulatory approvals in place by third quarter of FY27.

Provided an update on the acquisition of two injectable facilities, indicating progress and a timeline for final regulatory approvals.

Asked by Abdulkader Puranwala

3 min read 8 chapters

Detailed narrative

Q3 FY26 Performance Overview

OneSource Specialty Pharma Limited reported a challenging Q3 FY26, with revenue declining 26% year-on-year to INR 2,903 million. This revenue shortfall led to an EBITDA of INR 173 million. The company recorded an adjusted PAT loss of INR 472 million, translating to an adjusted EPS of negative 4.1 per share, primarily due to deferred revenues and resulting negative operating leverage.

Semaglutide Approval Delays and Revenue Impact

The primary factor impacting Q3 FY26 results was the delay in Canadian regulatory approval for semaglutide, particularly for a key partner like Dr. Reddy's, which was initially expected in January 2026. These approvals are now estimated to occur between 'now and May,' leading to deferred revenues. Consequently, the company anticipates the next two quarters (H2 FY26 and H1 FY27) to remain 'relatively soft' due to these delays and the absence of new Manufacturing and Supply Agreements (MSAs).

FY28 Guidance Reiteration and Confidence

Despite the near-term challenges, OneSource reiterated its FY28 guidance of $400 million in revenue and $160 million in EBITDA, excluding inorganic accretions. Management expressed high confidence in achieving these targets, citing expanding order books, upwardly revised customer forecasts, and strategic readiness for scale. They expect a Q4 FY27 exit run rate for both revenues and EBITDA to be a strong indicator of achieving the FY28 numbers.

Capacity Expansion and Operational Readiness

The company's aggressive capex of over INR 700 crores for capacity expansion is progressing well, with nearly three-quarters of the planned $100 million investment for the flagship site already committed, including $75 million for its expansion. By the end of FY27, OneSource expects to have approximately 200 million units of installed capacity. A four-month shutdown is underway at the Bangalore general injectable site to increase lyophilization and high-viscosity pre-filled syringe capabilities, which will enhance long-term capacity.

Biologics and Specialty Pharma Business Growth

OneSource is experiencing strong tailwinds in its nascent biologics business, driven by new FDA guidelines on biosimilars and the Biosecure Act, which have led to a near 4x increase in RFPs and a historic high funnel. The company onboarded a new US-based biosimilar major customer and secured approval for its first oncology asset, partnering with a top 10 US generic company, further diversifying its specialty offering.

Capital Structure and Debt Management

The company's cost of debt has improved significantly, now 200 basis points lower than last year, at less than 9% effective interest rate, following two credit rating upgrades. While capex funding has led to an increase in net debt, management is confident in maintaining a near-term net debt to EBITDA ratio of less than 1.5x and aims to be debt-free by 2028, excluding future capex for biologics.

Strategic Partnerships and Contract Renegotiations

OneSource is proactively working with partners to manage delayed approvals and increasing batch sizes. This includes deferring take-or-pay contracts while securing significant advances, and in some cases, invoking contractual obligations. This approach aims to build long-term partnerships and ensure mutual benefit, especially given the regulatory nature of the delays, and reprioritize business actions.

Acquisition of Injectable Facilities Update

The acquisition of two injectable facilities is progressing as planned, with the application submitted to the Stock Exchange. Management anticipates receiving all final regulatory approvals for this transaction by the third quarter of FY27. This acquisition is expected to further enhance the company's manufacturing capabilities and contribute to its strategic value.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls